免疫疗法：个性化肿瘤疫苗 - Suppr

Suppr

超能文献

Immunotherapy: personalizing tumour vaccines.

作者信息

Killock David

出版信息

Nat Rev Clin Oncol. 2015 Feb;12(2):64. doi: 10.1038/nrclinonc.2014.220. Epub 2014 Dec 16.

DOI:10.1038/nrclinonc.2014.220

PMID:25511189

Abstract

摘要

相似文献

Immunotherapy: personalizing tumour vaccines.

Nat Rev Clin Oncol. 2015 Feb;12(2):64. doi: 10.1038/nrclinonc.2014.220. Epub 2014 Dec 16.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.

Rekindling cancer vaccines.

Nat Biotechnol. 2016 Oct 11;34(10):1019-1024. doi: 10.1038/nbt.3690.

Human Tumor Antigens and Cancer Immunotherapy.

Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. Epub 2015 Jun 16.

Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164.

New checkpoint inhibitors ride the immunotherapy tsunami.

Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.

Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.

Hum Vaccin Immunother. 2014;10(11):3286-96. doi: 10.4161/hv.28886.

Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.

Leuk Res. 2010 Jul;34(7):850-1. doi: 10.1016/j.leukres.2010.03.013. Epub 2010 Mar 31.

[Cancer immunotherapy--current status].

Ther Umsch. 2006 Apr;63(4):262-6. doi: 10.1024/0040-5930.63.4.262.

本文引用的文献

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Immunotherapy: personalizing tumour vaccines.

Nat Rev Clin Oncol. 2015 Feb;12(2):64. doi: 10.1038/nrclinonc.2014.220. Epub 2014 Dec 16.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.

Rekindling cancer vaccines.

Nat Biotechnol. 2016 Oct 11;34(10):1019-1024. doi: 10.1038/nbt.3690.

Human Tumor Antigens and Cancer Immunotherapy.

Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. Epub 2015 Jun 16.

Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164.

New checkpoint inhibitors ride the immunotherapy tsunami.

Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.

Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.

Hum Vaccin Immunother. 2014;10(11):3286-96. doi: 10.4161/hv.28886.

Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.

Leuk Res. 2010 Jul;34(7):850-1. doi: 10.1016/j.leukres.2010.03.013. Epub 2010 Mar 31.

[Cancer immunotherapy--current status].

Ther Umsch. 2006 Apr;63(4):262-6. doi: 10.1024/0040-5930.63.4.262.

本文引用的文献

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.